
Dr. Osman Salih Osman Ahmed
Assistant Professor of Biochemistry
osmansa@agu.edu.bh
|
البريد الإلكتروني |
السيرة الذاتية | تحميل |
الباحث العلمي (جوجل) |
Go To Page
|
Dr. Osman graduated from Khartoum University, Sudan conferring the degrees of Bachelor of Medicine and Bachelor of Surgery (MBBS) in 2006. After graduation, he joined the Biochemistry Department at Khartoum University as a Teaching Assistant. In 2009, he was conferred MSc in Medical Biochemistry and get promoted to Lecturer. Dr. Osman obtained his PhD on the role of cholesterol metabolism in hepatic steatosis and glucose tolerance from Karolinska Institutet, Sweden (2013 – 2019). His PhD work led to the discovery of a group of molecules (PCSK9 and SOAT2 inhibitors) that have been patented for the treatment of cardiometabolic diseases. After his PhD, he was awarded the prestigious and internationally competitive Novo Nordisk Fellowship in Diabetes and Metabolism at Karolinska Institutet (2019 -2024). His postdoctoral work on neural control of liver inflammation and metabolism resulted in five publications. In 2024, Dr. Osman joined the Biochemistry Department at Arabian Gulf University, Bahrain as Assistant Professor.
- Ph.D. in Clinical Chemistry, Karolinska Institutet-Sweden, 2019
- M.Sc in Medical Biochemistry, University of Khartoum, Sudan, 2009
- MBBS in Medicine and Surgery, University of Khartoum-Sudan, 2006
- Liver and lipoproteins metabolism
- Glucose hoemostasis and insulin resistance
- Bioelectronic Medicine
- Statins regulate hepatic PNPLA3 expression through a mechanism that requires SREBF2 in human hepatic cells, Journal of Internal Medicine, in press
- Kupffer cells dictate hepatic responses to the atherogenic dyslipidemic insult, Nature Cardiovascular Research, 2024
- Hepatic stellate cell activation is regulated by the vagus nerve in systemic inflammation, Bioelectronic Medicine, 2023
- Soat2 ties cholesterol metabolism to β-oxidation and glucose tolerance in male mice, Journal of Internal Medicine, 2022
- Ezetimibe in combination with simvastatin reduces remnant-cholesterol without affecting biliary lipid concentrations in gallstone patients, Journal of the American Heart Association, 2018